Abstract
Inflamm-aging, that is the age-associated inflammatory status, is considered one of the most striking consequences of immunosenescence, as it is believed to be linked to the majority of age-associated diseases sharing an inflammatory basis. Nevertheless, evidence is emerging that inflamm-aging is at least in part independent from immunological stimuli. Moreover, centenarians who avoided or delayed major inflammatory diseases display markers of inflammation. In this paper we proposed a reappraisal of the concept of inflamm- aging, suggesting that its pathological effects can be independent from the total amount of pro-inflammatory mediators, but they would be rather associated with the anatomical district and type of cells where they are produced and where they primarily act.
Keywords: Inflammation, aging, centenarians, cell senescence, immunosenescence, immunological stimuli, pro-inflammatory mediators, markers, inflamm-aging, longevity
Current Pharmaceutical Design
Title:Immune System, Cell Senescence, Aging and Longevity - Inflamm-Aging Reappraised
Volume: 19 Issue: 9
Author(s): Annalaura Barbieri, Claudio Franceschi, Miriam Capri, Aurelia Santoro, Fiammetta Biondi, Maria Scurti, Elisa Pini, Elisa Cevenini, Morena Martucci, Elena Bellavista, Dario Vianello, Vincenzo Borelli, Laura Lomartire, Stefano Salvioli, Stella Lukas Yani, Federica Sevini, Laura Bucci, Rita Ostan, Elisa Fontanesi, Cristina Giuliani, Paolo Garagnani, Maria Giulia Bacalini, Chiara Pirazzini, Maria Conte, Catia Lanzarini and Daniela Monti
Affiliation:
Keywords: Inflammation, aging, centenarians, cell senescence, immunosenescence, immunological stimuli, pro-inflammatory mediators, markers, inflamm-aging, longevity
Abstract: Inflamm-aging, that is the age-associated inflammatory status, is considered one of the most striking consequences of immunosenescence, as it is believed to be linked to the majority of age-associated diseases sharing an inflammatory basis. Nevertheless, evidence is emerging that inflamm-aging is at least in part independent from immunological stimuli. Moreover, centenarians who avoided or delayed major inflammatory diseases display markers of inflammation. In this paper we proposed a reappraisal of the concept of inflamm- aging, suggesting that its pathological effects can be independent from the total amount of pro-inflammatory mediators, but they would be rather associated with the anatomical district and type of cells where they are produced and where they primarily act.
Export Options
About this article
Cite this article as:
Barbieri Annalaura, Franceschi Claudio, Capri Miriam, Santoro Aurelia, Biondi Fiammetta, Scurti Maria, Pini Elisa, Cevenini Elisa, Martucci Morena, Bellavista Elena, Vianello Dario, Borelli Vincenzo, Lomartire Laura, Salvioli Stefano, Lukas Yani Stella, Sevini Federica, Bucci Laura, Ostan Rita, Fontanesi Elisa, Giuliani Cristina, Garagnani Paolo, Giulia Bacalini Maria, Pirazzini Chiara, Conte Maria, Lanzarini Catia and Monti Daniela, Immune System, Cell Senescence, Aging and Longevity - Inflamm-Aging Reappraised, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090015
DOI https://dx.doi.org/10.2174/1381612811319090015 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity
Recent Patents on Anti-Infective Drug Discovery Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Current Pharmaceutical Design Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances
Current Topics in Medicinal Chemistry Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective
Current Cancer Drug Targets ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1
Current Neuropharmacology Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Synthesis of a Novel Gold(I) Complex and Evaluation of Its Anticancer Properties in Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Weekly Low-doses with Prolonged Infusion of Gemcitabine /Cisplatin for Multi-treated Metastatic Breast Cancer Patients
Current Cancer Therapy Reviews Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy
Current Radiopharmaceuticals Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Targeting Basal-Like Breast Cancers
Current Drug Targets The Accomplices of NF-κB Lead to Radioresistance
Current Protein & Peptide Science Diverse Roles of GADD45α in Stress Signaling
Current Protein & Peptide Science Synthesis and Biological Activity of New 4β-N-Heteroaryl Analogues of Podophyllotoxin
Letters in Drug Design & Discovery Theoretical Modelling of Potential Chk1 Inhibitors
Letters in Drug Design & Discovery TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology